Rapport Therapeutics, Inc. RAPP
Rapport Therapeutics, Inc. (Nasdaq: RAPP) is a CNS/neurology/psychiatry drug developer. Its lead program, RAP-219, is in Phase 3 for drug-resistant focal onset seizures. Its next catalyst on record is RAP-219 FOS open-label safety trial: initial data (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: RAP-219 FOS open-label safety trial — initial data (Q4 2026). 6 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| RAP-219 | drug-resistant focal onset seizures | small molecule | Phase 3 |
| RAP-219 | primary generalized tonic-clonic seizures | small molecule | Phase 3 |
| RAP-219 | bipolar mania | small molecule | Phase 2 |
| RAP-219 LAI formulation | across all RAP-219 indications | small molecule | Phase 1 |
| RAP-641 | chronic pain and migraine | small molecule | Pre-clinical |
| α9α10 nAChR modulators | hearing and vestibular disorders | small molecule | Pre-clinical |
Recent results and decisions
- Oct 20, 2026met Randomized Phase 2 (n=253) met primary endpoint: 3.1-point placebo-adjusted YMRS improvement at Week 3 (15.4 vs 12.3 points, p=0.045); CGI-BP-S secondary also met (0.4, p=0.024); well tolerated.
The trial met its primary endpoint, with RAP-219 achieving a 3.1-point placebo-adjusted improvement in the Young Mania Rating Scale (YMRS) total score at Week 3
Filing - Aug 5, 2026started Phase 3 program in FOS initiated in Q2 2026 with two parallel trials, FOCUS 1 and FOCUS 2, now enrolling patients.
The Company initiated its Phase 3 program in FOS in the second quarter of 2026, with two parallel trials—FOCUS 1 and FOCUS 2—enrolling patients.
Filing - May 7, 2026positive Phase 2a 8-week follow-up data (presented at AAN in April): 90% median reduction in clinical seizures vs baseline in weeks 9-12 and 59% in weeks 13-16; 80%/68% median reduction in long episodes; half-life now estimated at 22 days.
RAP-219 continued to demonstrate clinically meaningful improvements in long episodes (LEs) and clinical seizures during the follow-up period, with an 80% median reduction in LEs and 90% median reduction in clinical seizures compared to baseline in weeks 9-12
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.